KYTX - Kyverna Therapeutics, Inc.

QQQ $ 629.16 $ 3.02 (0.48 %)

DIA $ 475.58 $ 0.66 (0.14 %)

SPY $ 681.80 $ 2.23 (0.33 %)

TLT $ 90.21 $ -0.27 (-0.3 %)

GLD $ 368.20 $ -2.01 (-0.54 %)

Previous Close

$ 6.97

Open

$ 6.75

Bid

$ 6.50 x 445

Ask

$ 7.35 x 200

Day's Range

$ 6.61 - $ 7.05

52 Week Range

$ 1.78 - $ 8.45

Volume

368,433

Average Volume

Market Cap

301.42M

Beta (5Y Monthly)

$ 1.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-27-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-26-2024	12-31-2023	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Overweight on Kyvern...
10/30/2025 14:35:07

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...

Kyverna Therapeutics Announces Interim Pha...
10/29/2025 10:36:36

HC Wainwright & Co. Maintains Buy on Kyver...
10/27/2025 11:06:34

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the pr...

Reported Saturday, Kyverna Therapeutics Hi...
10/27/2025 06:54:32

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with d...

Kyverna Therapeutics To Discuss Interim Da...
10/22/2025 12:03:15

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...

Wells Fargo Maintains Overweight on Kyvern...
10/08/2025 14:24:16

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...

Kyverna Therapeutics Reports Phase 1 Data ...
09/24/2025 13:19:51

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (C...

Kyverna Therapeutics To Present Interim Da...
09/15/2025 17:03:56

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow upEnrollment for re...

HC Wainwright & Co. Maintains Buy on Kyver...
08/29/2025 12:38:48

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the pr...

Kyverna Therapeutics To Host Webcast At 11...
08/28/2025 12:15:05

kyverna-sets-pace-in-race-for-autoimmune-car-t-approval-by-2026

Kyverna Sets Pace In Race For Autoimmune C...
08/20/2025 19:29:12

William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy i...

William Blair Initiates Coverage On Kyvern...
08/20/2025 13:01:07

William Blair analyst Sami Corwin initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Outperform rating.

Kyverna Therapeutics Q2 EPS $(0.97) Beats ...
08/12/2025 20:21:44

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of ...

12 Health Care Stocks Moving In Tuesday's ...
07/15/2025 17:06:53

Kyverna Therapeutics Appoints Marc Grasso,...
06/30/2025 13:06:54

12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

with-trials-in-motion-cash-to-2027-can-kyvernas-next-data-drop-turn-the-stock-around

With Trials In Motion, Cash To 2027, Can K...
05/27/2025 19:42:54

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a r...

this-commercial-metals-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday

This Commercial Metals Analyst Turns Bulli...
05/27/2025 12:59:43

HC Wainwright & Co. Upgrades Kyverna Thera...
05/27/2025 10:56:59

HC Wainwright & Co. analyst Mitchell Kapoor upgrades Kyverna Therapeutics (NASDAQ:KYTX) from Neutral to Buy and raises t...

Kyverna Therapeutics Q1 EPS $(1.03) Misses...
05/13/2025 20:14:27

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate o...